Acadia Pharmaceuticals | ACAD - Current Assets


Acadia Pharmaceuticals reported $1.1B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.1B 33.9M Mar/2026
ALKERMES USD 1.36B 570.52M Mar/2026
Alnylam Pharmaceuticals USD 4.22B 168.65M Mar/2026
Biogen USD 9.19B 216.3M Mar/2026
BioMarin Pharmaceutical USD 4.61B 651.58M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Cara Therapeutics USD 31.54M 6.9M Dec/2025
Corcept Therapeutics USD 426.03M 59.43M Mar/2026
Cytokinetics USD 839.46M 77.51M Mar/2026
Eisai JPY 761.64B 79.24B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
J&J USD 59.17B 3.55B Mar/2026
Moderna USD 5.77B 774M Mar/2026
Neurocrine Biosciences USD 2.44B 86.6M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Prothena USD 339.2M 24.01M Mar/2026
PTC Therapeutics USD 2.25B 19.94M Mar/2026
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Ultragenyx Pharmaceutical USD 657M 294M Mar/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.73B 529.3M Mar/2026